Modality
Bispecific Ab
MOA
Cl18.2
Target
MET
Pathway
Checkpoint
Prostate Ca
Development Pipeline
Preclinical
~Nov 2013
→ ~Feb 2015
Phase 1
~May 2015
→ ~Aug 2016
Phase 2
~Nov 2016
→ ~Feb 2018
Phase 3
May 2018
→ Jan 2027
Phase 3Current
NCT07259322
161 pts·Prostate Ca
2018-05→2027-01·Not yet recruiting
161 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-01-109mo awayPh3 Readout· Prostate Ca
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027
P3
Not yet…
Catalysts
Ph3 Readout
2027-01-10 · 9mo away
Prostate Ca
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07259322 | Phase 3 | Prostate Ca | Not yet recr... | 161 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| RVM-274 | Revolution Medicines | Phase 3 | MET | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 | |
| Tiratapinarof | Intellia | NDA/BLA | APOC3 | |
| Talazasiran | Kymera | NDA/BLA | MET | |
| RAP-2478 | Rapport Ther | Phase 3 | MET |